TY - JOUR
T1 - Low response in eliciting neuraminidase inhibition activity of sera among recipients of a split, monovalent pandemic influenza vaccine during the 2009 pandemic
AU - Ito, Hiroko
AU - Nishimura, Hidekazu
AU - Kisu, Tomoko
AU - Hagiwara, Haruhisa
AU - Watanabe, Oshi
AU - Kadji, Francois Marie Ngako
AU - Sato, Ko
AU - Omiya, Suguru
AU - Takashita, Emi
AU - Nobusawa, Eri
N1 - Funding Information:
This work was financially supported by the Clinical Research Division of Sendai Medical Center and, in part, by a Health Labor Sciences Research Grant, Research on Emerging and Reemerging Infectious Diseases (to E.N.; no. H22-// Shinko-Ippan-001//) from the Ministry of Health, Labor and Welfare of Japan. The authors greatly appreciate Dr. Shigeyuki Itamura of Influenza Virus Research Center, National Institute of Infectious Diseases, Japan, for valuable discussion and Dr. Isolde Dapat and Enago (www.enago.jp) for English language review by native speakers.
Publisher Copyright:
© 2020 Ito et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2020/5
Y1 - 2020/5
N2 - Antibodies against influenza virus neuraminidase (NA) protein prevent releasing of the virus from host cells and spreading of infection foci and are considered the ‘second line of defence’ against influenza. Haemagglutinin inhibition antibody-low responders (HI-LRs) are present among influenza split vaccine recipients. The NA inhibition (NAI) antibody response in vaccinees is worth exploring, especially those in the HI-LRs population. We collected pre- and post-vaccination sera from 61 recipients of an inactivated, monovalent, split vaccine against A/H1N1pdm09 and acute and convalescent sera from 49 unvaccinated patients naturally infected with the A/H1N1pdm09 virus during the 2009 influenza pandemic. All samples were subjected to haemagglutinin inhibition (HI), NAI and neutralisation assays. Most paired sera from naturally infected patients exhibited marked elevation in the NAI activity, and seroconversion rates (SCR) among HI-LRs and HI-responders (HI-Rs) were 60% and 87%, respectively; however, those from vaccinees displayed low increase in the NAI activity, and the SCR among HI-LRs and HI-Rs were 0% and 12%, respectively. In both HI-LRs and HI-Rs, vaccination with the inactivated, monovalent, split vaccine failed to elicit the NAI activity efficiently in the sera of the naive population, compared with the natural infection. Hence, the improvement of influenza vaccines is warranted to elicit not only HI but also NAI antibodies.
AB - Antibodies against influenza virus neuraminidase (NA) protein prevent releasing of the virus from host cells and spreading of infection foci and are considered the ‘second line of defence’ against influenza. Haemagglutinin inhibition antibody-low responders (HI-LRs) are present among influenza split vaccine recipients. The NA inhibition (NAI) antibody response in vaccinees is worth exploring, especially those in the HI-LRs population. We collected pre- and post-vaccination sera from 61 recipients of an inactivated, monovalent, split vaccine against A/H1N1pdm09 and acute and convalescent sera from 49 unvaccinated patients naturally infected with the A/H1N1pdm09 virus during the 2009 influenza pandemic. All samples were subjected to haemagglutinin inhibition (HI), NAI and neutralisation assays. Most paired sera from naturally infected patients exhibited marked elevation in the NAI activity, and seroconversion rates (SCR) among HI-LRs and HI-responders (HI-Rs) were 60% and 87%, respectively; however, those from vaccinees displayed low increase in the NAI activity, and the SCR among HI-LRs and HI-Rs were 0% and 12%, respectively. In both HI-LRs and HI-Rs, vaccination with the inactivated, monovalent, split vaccine failed to elicit the NAI activity efficiently in the sera of the naive population, compared with the natural infection. Hence, the improvement of influenza vaccines is warranted to elicit not only HI but also NAI antibodies.
UR - http://www.scopus.com/inward/record.url?scp=85084626693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084626693&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0233001
DO - 10.1371/journal.pone.0233001
M3 - Review article
C2 - 32401814
AN - SCOPUS:85084626693
VL - 15
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 5
M1 - e0233001
ER -